Alcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS fell 100.0%, free cash flow was flat and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow ALC
Alcon (ALC) Piotroski F-score
Alcon's Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, down from 8 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | (2.00) |
| FY2024 | 8 | 1.00 |
| FY2023 | 7 | 3.00 |
| FY2022 | 4 | (3.00) |
| FY2021 | 7 | 3.00 |
| FY2020 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 3.17% | 3.40% | Pass | 1 |
| Positive operating cash flow | 2.27b | 2.08b | Pass | 1 |
| Rising return on assets | 3.17% | 3.40% | Fail | 0 |
| Cash flow above net income | 1.29b | 1.06b | Pass | 1 |
| Falling long-term leverage | 0.13 | 0.15 | Pass | 1 |
| Rising current ratio | 2.12 | 2.77 | Fail | 0 |
| No new shares issued | 493,200,000 | 494,400,000 | Pass | 1 |
| Rising gross margin | 55.24% | 55.61% | Fail | 0 |
| Rising asset turnover | 0.34 | 0.33 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 8 |
| BDX Becton, Dickinson and Company compare | 7 |
| RGEN Repligen Corporation compare | 6 |
| RMD ResMed Inc. compare | 6 |
| ALC Alcon | 6 |
| COO The Cooper Companies, Inc. compare | 5 |
| SOLV Solventum Corporation compare | 5 |
| BAX Baxter International Inc. compare | 4 |
| MDLN Medline Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover